Journal
JOURNAL OF DERMATOLOGICAL SCIENCE
Volume 39, Issue 1, Pages 33-38Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.jdermsci.2005.01.013
Keywords
SB-431542; TGF-beta; Smad; fibroblasts; contraction
Categories
Ask authors/readers for more resources
Background: Transforming growth factor (TGF)-beta induces fibroblast contraction, which is implicated in wound heating and keloid formation. SB-431542 is a novel specific inhibitor of TGF-beta type I receptor kinase activity. Objective : We sought to determine whether SB-431542 inhibited TGF-beta-induced fibroblast contraction. Methods : We used an in vitro type I collagen get contraction assay with normal or keloid dermal fibroblasts incorporated. Results : TGF-beta induced contraction of collagen gets with normal dermal fibroblasts incorporated, which was efficiently suppressed by SB-431542. Keloid fibroblasts showed higher basal contraction of collagen gets in the absence of TGF-beta than normal fibroblasts, which was enhanced by addition of TGF-beta. SB-431542 suppressed both the basal and TGF-beta-enhanced contraction of collagen gets by keloid fibroblasts. These inhibitory effects of SB-431542 were associated with suppression of TGF-beta-induced alpha-smooth muscle actin (alpha-SMA) expression and phosphorylation of Smad2 in normal and keloid fibroblasts. Conclusion : SB-431542 can suppress TGF-beta-induced contraction of collagen get by normal and keloid dermal fibroblasts. Importantly, SB-431542 can inhibit basal contraction of collagen get by keloid fibroblasts. These results suggest that an inhibitor of TGF-beta type I receptor kinase activity may have therapeutic potential for excessive skin contraction as observed in keloid. (c) 2005 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All. rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available